Provided by Tiger Fintech (Singapore) Pte. Ltd.

Corcept Therapeutics

62.24
-2.3600-3.65%
Post-market: 63.501.26+2.02%19:59 EDT
Volume:1.58M
Turnover:99.30M
Market Cap:6.57B
PE:50.60
High:65.40
Open:64.60
Low:61.94
Close:64.60
Loading ...

Corcept Therapeutics Inc (CORT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com
·
27 Feb

Corcept Therapeutics Reports Strong 2024 Financial Growth

TIPRANKS
·
27 Feb

Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates

Zacks
·
27 Feb

Corcept: Q4 Earnings Snapshot

Associated Press Finance
·
27 Feb

Corcept Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
27 Feb

Corcept Q4 Net Income Lower, Revenue Rises; Sets Guidance

MT Newswires Live
·
27 Feb

Corcept Therapeutics Q4 2024 GAAP EPS $0.26 Misses $0.42 Estimate, Sales $181.900M Miss $198.686M Estimate

Benzinga
·
27 Feb

BRIEF-Corcept Therapeutics Q4 EPS USD 0.26 Vs. IBES Estimate USD 0.43

Reuters
·
27 Feb

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update

Business Wire
·
27 Feb

Corcept (CORT) Q4 Earnings Report Preview: What To Look For

StockStory
·
25 Feb

Should Janus Henderson Small Cap Growth Alpha ETF (JSML) Be on Your Investing Radar?

Zacks
·
25 Feb

Corcept Therapeutics Inc expected to post earnings of 43 cents a share - Earnings Preview

Reuters
·
25 Feb

Corcept Therapeutics Incorporated (CORT): the Best Performing Pharma Stock So Far in 2025

Insider Monkey
·
24 Feb

Is Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF (GSSC) a Strong ETF Right Now?

Zacks
·
18 Feb

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call

Business Wire
·
13 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
12 Feb

5 Balance Sheet Powerhouses To Consider

GuruFocus.com
·
11 Feb

Corcept Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow Jones
·
07 Feb

Corcept Therapeutics: Leveraging Korlym Growth and CATALYST Study for Market Expansion and Long-term Growth

TIPRANKS
·
07 Feb

3 US Growth Companies With High Insider Ownership Expecting Up To 22% Revenue Growth

Simply Wall St.
·
05 Feb